2014
DOI: 10.1039/c4ob01436g
|View full text |Cite
|
Sign up to set email alerts
|

Total synthesis and biological evaluation of atrop-O-benzyl-desmethylabyssomicin C

Abstract: The total synthesis of desmethylabyssomicin C analogue 1 was accomplished using diastereotopos-selective ring closing metathesis and Nozaki-Hiyama-Kishi cyclization as the key steps. The synthetic analogue retained its antibacterial activity against methicillin-resistant S. aureus strains, whereas its cytotoxicity decreased for three orders of magnitude, as compared to atrop-abyssomicin C.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
23
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(23 citation statements)
references
References 17 publications
0
23
0
Order By: Relevance
“…Though concise and relatively high yielding, this synthetic approach has since been paralleled or superseded by alternate strategies; 53 notably Bihelovic and Saicic's approach, which avoids epoxide ring opening of the tetronate in the hope of higher tolerance in the generation of analogues for SAR studies. [54][55][56] Scheme 4: Convergent synthesis of atrop-abyssomicin (24) via connection of spirotetronate intermediate 25 with aldehyde 26 over 6 steps to give 27, which is subjected to ring closing metathesis, oxidation and final deprotection to give 24.…”
Section: Abyssomicin C: a Promising Antibacterial For Tuberculosismentioning
confidence: 99%
“…Though concise and relatively high yielding, this synthetic approach has since been paralleled or superseded by alternate strategies; 53 notably Bihelovic and Saicic's approach, which avoids epoxide ring opening of the tetronate in the hope of higher tolerance in the generation of analogues for SAR studies. [54][55][56] Scheme 4: Convergent synthesis of atrop-abyssomicin (24) via connection of spirotetronate intermediate 25 with aldehyde 26 over 6 steps to give 27, which is subjected to ring closing metathesis, oxidation and final deprotection to give 24.…”
Section: Abyssomicin C: a Promising Antibacterial For Tuberculosismentioning
confidence: 99%
“…Presently, thirty-two natural abyssomicins have been identified, and numerous derivatives were synthesized [ 27 , 28 , 29 , 30 , 31 , 34 , 35 , 39 , 40 , 41 , 42 , 49 , 50 , 51 , 52 ]. Out of all the abyssomicins screened for antimicrobial activity, only four natural abyssomicins (abyssomicin 2, C, J and atrop-abyssomicin C) [ 27 , 28 , 29 , 30 , 35 ] and nine synthetic derivatives were active ( Table 1 and Table 2 ) [ 24 , 31 , 39 , 40 , 41 , 42 , 51 ].…”
Section: Structural Classification and Bioactivitymentioning
confidence: 99%
“…Presently, thirty-two natural abyssomicins have been identified, and numerous derivatives were synthesized [ 27 , 28 , 29 , 30 , 31 , 34 , 35 , 39 , 40 , 41 , 42 , 49 , 50 , 51 , 52 ]. Out of all the abyssomicins screened for antimicrobial activity, only four natural abyssomicins (abyssomicin 2, C, J and atrop-abyssomicin C) [ 27 , 28 , 29 , 30 , 35 ] and nine synthetic derivatives were active ( Table 1 and Table 2 ) [ 24 , 31 , 39 , 40 , 41 , 42 , 51 ]. Active abyssomicins against Gram-positive bacteria, including Micrococcus luteus , Bacillus thuringiensis , Enterococcus faecalis , MRSA, and vancomycin-resistant S. aureus (VRSA) strains are abyssomicin C and its atropoisomer, 4 atrop-abyssomicin C derivatives (Benzyl ether derivative, Chloro derivative, and two diastereoisomeric methoxymethyl (MOM) ethers derivatives), atrop-O-benzyl-desmethylabyssomicin C, oxidized derivative of abyssomicin I, acetyl abyssomicin C, 3-dithiolane atrop -abyssomicin C, and dithiolane abyssomicin C, and abyssomicin 2 ( Table 1 ) [ 30 , 31 , 32 , 33 , 34 , 37 , 42 , 51 , 57 ].…”
Section: Structural Classification and Bioactivitymentioning
confidence: 99%
See 1 more Smart Citation
“…[598], shikimic acids and pinitol [599], carbasugars [600], madangamine D ( a later step forms a macrocyclic amine via RCM) [601], the kaurene core [602], various securinega alkaloids [603], a labyssomicin C derivative (e.g. 228 in a moderately diastereoselective RCM using a substrate featuring diastereotopic vinyl groups) [604], the crotogoudin ring system [605], tetrahydrocannabinol derivatives (e.g. 229) [606], diaminocyclohexenes [607], maeocrystal V (an earlier step in the synthesis employs enantioselective rhodium carbene-mediated C-H activation) [608], tamiflu (e.g.…”
Section: )mentioning
confidence: 99%